scholarly journals High Dose ESAs Are Associated with High iPTH Levels in Hemodialysis Patients with End-Stage Kidney Disease: A Retrospective Analysis

2015 ◽  
Vol 3 ◽  
Author(s):  
Lan Chen ◽  
Yi-Sheng Ling ◽  
Chun-Hua Lin ◽  
Jin-Xuan He ◽  
Tian-Jun Guan
Keyword(s):  
Kidney Disease ◽  
Retrospective Analysis ◽  
Hemodialysis Patients ◽  
High Dose ◽  
End Stage Kidney Disease ◽  
End Stage

scholarly journals Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End‐Stage Kidney Disease

2020 ◽  
Vol 9 (13) ◽  
Author(s):  
Magdalene M. Assimon ◽  
Lily Wang ◽  
Patrick H. Pun ◽  
Wolfgang C. Winkelmayer ◽  
Jennifer E. Flythe
Keyword(s):  
Risk Factors ◽  
Kidney Disease ◽  
Cardiac Death ◽  
Medication Use ◽  
Torsades De Pointes ◽  
Hemodialysis Patients ◽  
Qt Prolongation ◽  
End Stage Kidney Disease ◽  
Drug Induced ◽  
End Stage

Background The rate of sudden cardiac death in the hemodialysis population exceeds that of the general population by >20‐fold. Hemodialysis patients may be particularly susceptible to sudden cardiac death provoked by drug‐induced QT prolongation because of their substantial cardiovascular disease burden, exposure to electrolyte shifts during dialysis, and extensive polypharmacy. However, population‐specific data regarding the frequency and patterns of QT prolonging medication use are limited. Methods and Results We conducted a descriptive drug utilization study using 3 administrative databases, the United States Renal Data System, MarketScan, and Medicare claims. We characterized the extent and patterns of QT prolonging medication use by adult hemodialysis patients and individuals without end‐stage kidney disease annually from 2012 to 2016. We also identified instances of high‐risk QT prolonging medication use among hemodialysis patients. In total, 338 515 hemodialysis patients and 40.7 million individuals without end‐stage kidney disease were studied. Annual utilization rates of QT prolonging medications with known torsades de pointes risk in hemodialysis patients were ~1.4 to ~2.5 times higher than utilization rates in individuals without end‐stage kidney disease. Hemodialysis patients with demographic and clinical risk factors for drug‐induced QT prolongation were exposed to medications with known torsades de pointes risk more often than patients without risk factors. Conclusions Hemodialysis patients use QT prolonging medications with known torsades de pointes risk more extensively than individuals without end‐stage kidney disease. Given the widespread use and instances of high‐risk prescribing, future studies evaluating the cardiac safety of these drugs in the hemodialysis population are needed.

scholarly journals The Effectiveness of Depression Treatment for Adults with End-Stage Kidney Disease: A Systematic Review

Kidney360 ◽  
2021 ◽  
pp. 10.34067/KID.0003142020
Author(s):  
Pavan Chopra ◽  
Chelsea K. Ayers ◽  
Jennifer R. Antick ◽  
Devan Kansagara ◽  
Karli Kondo
Keyword(s):  
Systematic Review ◽  
Kidney Disease ◽  
Usual Care ◽  
Observational Studies ◽  
Depression Treatment ◽  
High Dose ◽  
Depression Severity ◽  
End Stage Kidney Disease ◽  
Review Team ◽  
End Stage

Adults with dialysis-dependent end-stage kidney disease (ESKD) experience higher rates of depression than the general population, yet efficacy of depression treatments in this population is not well understood. We conducted a systematic review of the benefits and harms of depression treatment in adults with ESKD. We searched multiple data sources through June 2020 for English-language controlled trials that compared interventions for depression in adults with ESKD to another intervention, placebo, or usual care, and reported depression treatment-related outcomes. Observational studies were included for harms. Two investigators independently screened all studies using pre-specified criteria. One reviewer abstracted data on study design, interventions, implementation characteristics, and outcomes, and a second reviewer confirmed. Two reviewers independently assessed study quality and resolved any discords through discussion or a third reviewer. Strength of evidence (SOE) was assessed and agreed upon by review team consensus. We qualitatively analyzed the data and present syntheses in text and tables. We included 26 RCTs and 3 observational studies. SSRIs were the most studied type of drug and the evidence was largely insufficient. We found moderate SOE that long-term, high-dose Vitamin D3 is ineffective for reducing depression severity. Cognitive behavioral therapy (CBT) is more effective than (undefined) psychotherapy and placebo for depression improvement and quality of life (low SOE), and acupressure is more effective than usual care or sham acupressure to reduce depression severity (low SOE). There is limited research evaluating treatment for depression in adults with ESKD, and existing studies may not be generalizable to adults in the US. Studies suffer from limitations related to methodological quality or reporting. More research replicating studies of promising interventions in U.S. populations with larger samples is needed.

Iliopsoas Abscess in Hemodialysis Patients With End‐Stage Kidney Disease

2019 ◽  
Vol 23 (6) ◽  
pp. 534-541
Author(s):  
Yusuke Kawai ◽  
Masataka Banshodani ◽  
Misaki Moriishi ◽  
Tomoyasu Sato ◽  
Sadanori Shintaku ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Hemodialysis Patients ◽  
End Stage Kidney Disease ◽  
Iliopsoas Abscess ◽  
End Stage

scholarly journals Components of quality of life in hemodialysis patients from family caregivers’ perspective: a qualitative study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Sima Sadat Hejazi ◽  
Meimanat Hosseini ◽  
Abbas Ebadi ◽  
Hamid Alavi Majd
Keyword(s):  
Quality Of Life ◽  
Content Analysis ◽  
Kidney Disease ◽  
Family Caregivers ◽  
Hemodialysis Patients ◽  
End Stage Kidney Disease ◽  
The Family ◽  
End Stage ◽  
The Impact

Abstract Background Patients with end-stage kidney disease experience serious complications which affect their lives. Few studies have investigated the patients’ quality of life qualitatively from the perspective of family caregivers as the closest individuals to the patients. The family caregivers are directly involved in the patients’ disease progression and observe the changes, problems, and complications of disease and hemodialysis. This study aimed to explain the components of quality of life in hemodialysis patients from the family caregivers’ perspective. Methods In this qualitative inductive content analysis, 16 family caregivers of hemodialysis patients, presenting to the teaching hospitals of Tehran, Iran, were enrolled via maximum-variation purposive sampling; sampling continued until reaching data saturation. The data collection method included in-depth semi-structured interviews. Also, an inductive content analysis was carried out based on Elo and Kyngas’ method. Results A total of 311 codes, 19 subcategories, eight generic categories, and three main categories were extracted in this study. The main (and the generic categories) included mental and psychological problems (depressive mood, incompatibility and reduced tolerance, mental exhaustion, and deprivation of basic needs), social disruption (social isolation and social threats), and physical problems (general complications and disabilities and defects in the normal functioning of organs). Conclusion Family caregivers can be valuable information sources for formal caregivers to plan treatment for chronically ill patients who are mainly cared for at home. The present results can help us increase the existing knowledge on the impact of end-stage kidney disease and hemodialysis on the patients’ quality of life. It seems that addressing the issues related to quality of life, mentioned by the caregivers, can positively affect the patients’ quality of life and even reduce the caregivers’ burden.

Cumulative ionizing radiation exposure in patients with end stage kidney disease: a 6-year retrospective analysis

2011 ◽  
Vol 37 (4) ◽  
pp. 632-638 ◽  
Author(s):  
Joe Coyle ◽  
Sinead Kinsella ◽  
Siobhain McCarthy ◽  
Sebastian MacWilliams ◽  
Patrick McLaughlin ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Ionizing Radiation ◽  
Radiation Exposure ◽  
Retrospective Analysis ◽  
End Stage Kidney Disease ◽  
End Stage ◽  
Ionizing Radiation Exposure

scholarly journals Retrospective analysis of arteriovenous fistula patency and failure in patients on dialysis for end-stage kidney disease in the Gaza strip

The Lancet ◽  
2019 ◽  
Vol 393 ◽  
pp. S3
Author(s):  
Abdelrahman Alshaikh Ahmad ◽  
Mohammed Al.Qudairi ◽  
Abdulah Abo Jalambo ◽  
Mohammed Elser ◽  
Khalid Alnahhal ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Arteriovenous Fistula ◽  
Retrospective Analysis ◽  
Gaza Strip ◽  
End Stage Kidney Disease ◽  
The Gaza Strip ◽  
End Stage

Myoglobin Elimination in End Stage Kidney Disease Patients on Renal Replacement Treatment

1993 ◽  
Vol 16 (9) ◽  
pp. 659-661 ◽  
Author(s):  
V. Stefanović ◽  
M. Bogićević ◽  
M. Mitić
Keyword(s):  
Peritoneal Dialysis ◽  
Kidney Disease ◽  
Serum Levels ◽  
Hemodialysis Patients ◽  
Peritoneal Membrane ◽  
End Stage Kidney Disease ◽  
Replacement Treatment ◽  
End Stage ◽  
Hemodialysis Membrane ◽  
Serum Myoglobin

Increased serum myoglobin levels were previously found in patients with chronic renal failure. In this report we have studied the effects of dialysis on myoglobin elimination in patients on CARD, IPD, cuprophan and polyacrylonitrile (PAN) membrane hemodialysis. Peritoneal dialysis removed a significant amount of myoglobin, CAPD 480 ± 65 μg/day, IPD 270 ± 25 μg/12 h treatment, while with cuprophan dialysis none, and with PAN dialysis only an insignificant amount of myoglobin. The serum myoglobin levels were 250 ± 18 and 264 ± 14 μg/l on cuprophan and a 3 month dialysis on PAN membrane, respectively. Markedly increased serum levels were also found in CAPD and IPD patients on peritoneal dialysis, 227 ± 25 and 286 ± 32 μg/l respectively. This study has shown that there is an increased serum myoglobin concentration in end-stage kidney disease patients on dialysis. Although peritoneal membrane is permeable to myoglobin, a relatively small amount is removed, and the serum level in CAPD and IPD patients was not significantly different from the serum myoglobin concentration in hemodialysis patients. Furthermore myoglobin could not be removed by hemodialysis membrane and an analysis of its important extrarenal catabolism level points were analyzed.

Mortality and Hospitalizations among Sickle Cell Disease Patients with End-Stage Kidney Disease Initiating Dialysis

2021 ◽  
pp. 1-9
Author(s):  
Kabir O. Olaniran ◽  
Nwamaka D. Eneanya ◽  
Sophia H. Zhao ◽  
Norma J. Ofsthun ◽  
Franklin W. Maddux ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Kidney Disease ◽  
Sickle Cell ◽  
Mortality Risk ◽  
Geographic Region ◽  
Sensitivity Analyses ◽  
High Dose ◽  
Cell Disease ◽  
End Stage Kidney Disease ◽  
End Stage

<b><i>Background:</i></b> Sickle cell disease (SCD) is the most common inherited hematological disorder and a well-described risk factor for end-stage kidney disease (ESKD). Mortality and hospitalizations among patients with SCD who develop ESKD remain understudied. Furthermore, prior studies focused only on SCD patients where ESKD was caused by SCD. We aimed to describe mortality and hospitalization risk in all SCD patients initiating dialysis and explore risk factors for mortality and hospitalization. <b><i>Methods:</i></b> We performed a national observational cohort study of African American ESKD patients initiating dialysis (2000–2014) in facilities affiliated with a large dialysis provider. SCD was identified by diagnosis codes and matched to a reference population (non-SCD) by age, sex, dialysis initiation year, and geographic region of care. Sensitivity analyses were conducted by restricting to patients where SCD was recorded as the cause of ESKD. <b><i>Results:</i></b> We identified 504 SCD patients (mean age: 47 ± 14 years; 48% females) and 1,425 reference patients (mean age: 46 ± 14 years; 49% females). The median follow-up was 2.4 (IQR 1.0–4.5) years. Compared to the reference, SCD was associated with higher mortality risk (hazard ratio 1.66; 95% confidence interval [CI]: 1.36–2.03) and higher hospitalization rates (incidence rate ratio 2.12; 95% CI: 1.88–2.38) in multivariable analyses. Exploratory multivariable mortality risk models showed the largest mortality risk attenuation with the addition of time-varying hemoglobin and high-dose erythropoietin, but the association of SCD with mortality remained significant. Sensitivity analyses (restricted to ESKD caused by SCD) also showed significant associations between SCD and mortality and hospitalizations, but with larger effect estimates. High-dose erythropoietin was associated with the highest risk for mortality and hospitalization in SCD. <b><i>Conclusions:</i></b> Among ESKD patients, SCD is associated with a higher risk for mortality and hospitalization, particularly in patients where SCD is identified as the cause of ESKD.

Sign in / Sign up

Export Citation Format

Share Document